2. Search Result
Search Result
Results for "

FAPI-2

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128642
    FAPI-2

    		FAP Cancer
    FAPI-2 is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as 68Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose [2] .
    FAPI-2
  • HY-128642A
    FAPI-2 TFA

    		FAP Cancer
    FAPI-2 TFA is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as 68Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 TFA has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose [2] .
    FAPI-2 TFA
  • HY-164364B
    DOTAGA.(SA.FAPi)2 analogue TFA

    		FAP Cancer
    DOTAGA.(SA.FAPi)2 analogue TFA is a DOTAGA.(SA.FAPi)2 TFA (HY-164364A) analogue, in which the ligand and the chelator are identical to those of DOTAGA.(SA.FAPi)2 TFA. DOTAGA.(SA.FAPi)2 TFA is a potent dimeric fibroblast-activation protein inhibitor (FAPi) .
    DOTAGA.(SA.FAPi)2 analogue TFA
  • HY-164364A
    DOTAGA.(SA.FAPi)2 TFA

    		FAP Cancer
    DOTAGA.(SA.FAPi)2 TFA is a potent dimeric fibroblast-activation protein inhibitor (FAPi). DOTAGA.(SA.FAPi)2 TFA has the potential for cancer diagnosis research .
    DOTAGA.(SA.FAPi)2 TFA
  • HY-159768A
    DOTAGA.Glu.(FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAGA.Glu.(FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .
    DOTAGA.Glu.(FAPi)2
  • HY-159767A
    (S)-DOTAGA.(SA.FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    (S)-DOTAGA.(SA.FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .
    (S)-DOTAGA.(SA.FAPi)2